<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00251537</url>
  </required_header>
  <id_info>
    <org_study_id>LTB4 200501</org_study_id>
    <nct_id>NCT00251537</nct_id>
  </id_info>
  <brief_title>A Pilot Study of LTB4 in HIV-1 Infected Adults</brief_title>
  <official_title>A Pilot Study Assessing Safety and Antiretroviral Activity of Intravenously Administered LTB4 in HIV-1 Infected Adults With a CD4 Count Greater Than 250 Cells/mm3 and a Viral Load Greater Than 5,000 Copies/mL, and Who Have Not Received Antiretroviral Therapy Within Two Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LTB4 Sweden AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LTB4 Sweden AB</source>
  <brief_summary>
    <textblock>
      This is a pilot study to assess the safety and antiretroviral activity of a naturally&#xD;
      occuring substance known as Leukotriene B4(LTB4). The aim of the study is to determine the&#xD;
      effect of LTB4 on viral load during a period of 6 weeks, 4 weeks of active treatment and 2&#xD;
      additional weeks after the end of active treatment for safety follow-up. 40 patients in seven&#xD;
      clinics in Canada will be randomized into three treatment arms, either of two doses of LTB4&#xD;
      or placebo. Study drug is administered intravenously once daily. LTB4 can activate and&#xD;
      stimulate various white blood cells and by the activation release natural substances in the&#xD;
      body and this process is an important part of the body's defense against infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot study is to investigate whether LTB4, administered at a dose that&#xD;
      provides an increase in alfa-defensin release from neutrophils, can affect HIV viral load in&#xD;
      HIV-1 infected individuals. The safety, tolerability and effect will be assessed of 28 days&#xD;
      of daily intravenous dosing of LTB4 on HIV viral load. Safety and tolerability will also be&#xD;
      assessed.&#xD;
&#xD;
      The study is randomized, double-blind, placebo controlled. All subjects will be randomly&#xD;
      assigned to one of three treamtent groups, LTB4 at two different dose levels or corresponding&#xD;
      placebo. Treatment duration is 4 weeks and follow-up period is 2 weeks. Subjects will visit&#xD;
      the clinic on a daily basis during the treatment period to receive a daily intravenous&#xD;
      injection of the study drug. 40 subjects will be enrolled, seven clinics in Canada will&#xD;
      participate in the study.&#xD;
&#xD;
      Primary endpoint: Change in viral load over the treatment period of 28 days. Secondary&#xD;
      endpoint: CD4, CD8 and neutrophil counts, alfa-defensins and CC-che, mokine release in blood.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date>August 2006</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the effect of 28 days of daily dosing of LTB4 on HIV viral load</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of 28 days of daily dosing</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess effects on CD4 and CD8 counts of 28 days of daily dosing</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess effects on neutrophil counts of 28 days of dosing</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess effects on release of alfa-defensins and CC-chemokines in blood on day s 1, 14 and 28</measure>
  </secondary_outcome>
  <enrollment>40</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LTB4</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects between 18 and 65 years of age&#xD;
&#xD;
          2. Diagnosis of HIV-1 infection&#xD;
&#xD;
          3. Plasma HIV RNA level greater or equal to 5,000 copies/mL at the screening visit&#xD;
&#xD;
          4. A CD4 cell count equal or greater than 250 cells/mm3 and CD4 fraction equal or greater&#xD;
             than 14% at the screening visit within one month of study entry&#xD;
&#xD;
          5. No ART within two months of study entry&#xD;
&#xD;
          6. Karnofsky score equal to or above 80&#xD;
&#xD;
          7. If female of childbearing potential, a negative serum pregnancy test at screening.&#xD;
&#xD;
          8. In the opinion of the investigator, the subject will be able to comply with the&#xD;
             requirements of the protocol, including ability to present for all required visits&#xD;
&#xD;
          9. Subject is capable of understanding and signing an informed consent form&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          1. Primary HIV-1 infection&#xD;
&#xD;
          2. Use of investigational therapy in the preceding month prior to screening visit&#xD;
&#xD;
          3. Prior screening for entry into this study&#xD;
&#xD;
          4. Use of G-CSF, GM-CSF, IL-2, IFNs, erythropoietin, systemic or inhaled steroids within&#xD;
             one month of the screening visit&#xD;
&#xD;
          5. HIV-vaccine within one year of the screening visit&#xD;
&#xD;
          6. Concurrent disease or conditions that may present a risk to the subjects&#xD;
&#xD;
          7. Females who are pregnant or breast feeding&#xD;
&#xD;
          8. History of any malignancy or any active malignancy, except cutaneous Kaposis sarcoma&#xD;
&#xD;
          9. Unexplained temperature of 38.5 degrees Celsius&#xD;
&#xD;
         10. Chronic diarrhea (&gt;3 liquid stools per day persisting for 15 days) within one month&#xD;
             prior to study entry&#xD;
&#xD;
         11. Calculated creatinine clearance outside normal limits&#xD;
&#xD;
         12. Urinalysis: hemoglobinuria, present&#xD;
&#xD;
         13. Liver transaminases &gt; 3 x ULN&#xD;
&#xD;
         14. Absolute neutrophil count &lt; 500/mm3&#xD;
&#xD;
         15. Hemoglobin &lt; 8.0g/dL&#xD;
&#xD;
         16. Platelet count &lt; 75,000/mm3&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Lalonde, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Montreal Chest Institute, Montreal, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for HIV/AIDS, St Pauls Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ottawa Hospital (General Campus)</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Institute of the McGill University Health Centre</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Quebec</name>
      <address>
        <city>Ste-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>July 2006</verification_date>
  <study_first_submitted>November 9, 2005</study_first_submitted>
  <study_first_submitted_qc>November 9, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2005</study_first_posted>
  <last_update_submitted>July 7, 2006</last_update_submitted>
  <last_update_submitted_qc>July 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 10, 2006</last_update_posted>
  <keyword>Pilot study</keyword>
  <keyword>Randomized</keyword>
  <keyword>Placebo-controlled</keyword>
  <keyword>Double-blind</keyword>
  <keyword>Effect on viral load</keyword>
  <keyword>LTB4</keyword>
  <keyword>HIV-1 infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

